SHREVEPORT, La. - Giant cell arteritis, also known as temporal arteritis, is a less common condition where people get inflammation of the arteries that go to the head and neck. Symptoms include, head ...

A new point-of-care prediction tool that uses clinical and ultrasonography findings has good accuracy for identifying giant cell arteritis among patients seen in fast-track clinics. Investigators ...

For patients with giant cell arteritis (GCA), a higher total vascular score (TVS) based on 18F-fluorodeoxyglucose (FDG) positron emission tomography (PET) imaging at diagnosis is associated with a ...

Patients with giant cell arteritis started tocilizumab therapy an average of 43 days after diagnosis, partly because of delays in insurance approval. Overall, 82 patients (average age, 73 years; 60% ...

(RTTNews) - AbbVie Inc. (ABBV) Thursday announced positive results from SELECT-GCA Phase 3 of Upadacitinib 15 mg, once daily in combination with a 26-week steroid taper regimen in adults with giant ...

Out of 165 older patients in whom GCA was strongly suspected, 73 (44%) had the telltale "halo" sign on temporal artery ultrasound; and of those, the GCA diagnosis was unchanged when re-examined 2 ...

NORTH CHICAGO, Ill., April 29, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced the U.S. Food and Drug Administration (FDA) has approved RINVOQ ® (upadacitinib), 15 mg, once daily, for the ...

Giant cell arteritis (GCA), also known as temporal arteritis, is an autoimmune disease of medium and large arteries, characterized by granulomatous inflammation of the three-layered vessel wall, which ...